| Dr Jeffrey John Mathews, MD | |
|
2501 Kuser Rd, Hamilton, NJ 08691-3386 | |
| (609) 585-8800 | |
| Not Available |
| Full Name | Dr Jeffrey John Mathews |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 19 Years |
| Location | 2501 Kuser Rd, Hamilton, New Jersey |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083825756 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MT185932 (Pennsylvania) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 25MA08941400 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The New Jersey Imaging Network, Llc | 2860633492 | 64 |
News Archive
A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.
Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).
University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases - thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.
Researchers at the Johns Hopkins Bloomberg School of Public Health have found evidence of a role for neighborhood immunity in determining risk of dengue infection.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases.
› Verified 5 days ago
| Entity Name | Radiology Affiliates Of Central New Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811994791 PECOS PAC ID: 1759277239 Enrollment ID: O20040330000560 |
News Archive
A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.
Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).
University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases - thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.
Researchers at the Johns Hopkins Bloomberg School of Public Health have found evidence of a role for neighborhood immunity in determining risk of dengue infection.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases.
› Verified 5 days ago
| Entity Name | The New Jersey Imaging Network, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629327887 PECOS PAC ID: 2860633492 Enrollment ID: O20130724000791 |
News Archive
A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.
Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).
University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases - thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.
Researchers at the Johns Hopkins Bloomberg School of Public Health have found evidence of a role for neighborhood immunity in determining risk of dengue infection.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases.
› Verified 5 days ago
| Entity Name | Imaging Group Of Delaware Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164421574 PECOS PAC ID: 0547152472 Enrollment ID: O20170512000055 |
News Archive
A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.
Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).
University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases - thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.
Researchers at the Johns Hopkins Bloomberg School of Public Health have found evidence of a role for neighborhood immunity in determining risk of dengue infection.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey John Mathews, MD 2501 Kuser Rd, Hamilton, NJ 08691-3386 Ph: (609) 585-8800 | Dr Jeffrey John Mathews, MD 2501 Kuser Rd, Hamilton, NJ 08691-3386 Ph: (609) 585-8800 |
News Archive
A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.
Sunovion Pharmaceuticals Inc. today announced post-hoc analysis results of a positive Phase 3 placebo-controlled clinical study, as well as interim data from a long-term open-label extension study evaluating Latuda (lurasidone HCI) in children and adolescents (10 to 17 years of age) with major depressive episodes associated with bipolar I disorder (bipolar depression).
University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases - thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation.
Researchers at the Johns Hopkins Bloomberg School of Public Health have found evidence of a role for neighborhood immunity in determining risk of dengue infection.
Penn Medicine researchers have discovered that hypermethylation - the epigenetic ability to turn down or turn off a bad gene implicated in 10 to 30 percent of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD) - serves as a protective barrier inhibiting the development of these diseases.
› Verified 5 days ago
Steven L Meshkov, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2501 Kuser Rd, Hamilton, NJ 08691 Phone: 609-585-8800 Fax: 609-585-1825 | |
Joseph J. Kim, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 2501 Kuser Rd, Hamilton, NJ 08691 Phone: 609-585-8800 Fax: 609-585-1825 | |
Gustavo Sanchez, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 2501 Kuser Rd, Hamilton, NJ 08691 Phone: 609-585-8800 Fax: 609-585-1825 | |
Roy M Prager, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 2501 Kuser Rd, Hamilton, NJ 08691 Phone: 609-585-8800 Fax: 609-585-1825 | |
Richard F. Scafidi, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 2501 Kuser Rd, Hamilton, NJ 08691 Phone: 609-585-8800 Fax: 609-585-1825 | |
Paul J. Weiser, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 2501 Kuser Rd, Ste 514, Hamilton, NJ 08691 Phone: 609-585-8800 Fax: 609-585-1825 |